| scholarly article | Q13442814 |
| P50 | author | Karen H Costenbader | Q87706447 |
| P2093 | author name string | Chaim Putterman | |
| Mimi Kim | |||
| Anna Broder | |||
| Henny Billett | |||
| Irina Murakhovskaya | |||
| Joel Neugarten | |||
| Wenzhu B Mowrey | |||
| P2860 | cites work | IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis | Q28191996 |
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Antiphospholipid antibody syndrome and renal disease | Q32064111 | ||
| Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis | Q33358476 | ||
| The geoepidemiology of the antiphospholipid antibody syndrome | Q33387143 | ||
| Democratizing information creation from health care data for quality improvement, research, and education-the Montefiore Medical Center Experience | Q33572764 | ||
| Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study | Q33766242 | ||
| Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort | Q33871715 | ||
| Epidemiology of the antiphospholipid antibody syndrome | Q33916234 | ||
| Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort | Q34005307 | ||
| Increased risk of death in pediatric and adult patients with ESRD secondary to lupus | Q34351153 | ||
| Pathogenic mechanisms mediating antiphospholipid syndrome | Q34404108 | ||
| Atherosclerosis in systemic lupus erythematosus | Q35525108 | ||
| Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. | Q35895238 | ||
| Systemic lupus erythematosus, atherosclerosis, and autoantibodies | Q36242825 | ||
| Increased hospitalizations and death in patients with ESRD secondary to lupus | Q37000849 | ||
| Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism | Q37088895 | ||
| Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus | Q37158591 | ||
| Antiphospholipid syndrome: frequency, main causes and risk factors of mortality | Q37729831 | ||
| Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk | Q37854186 | ||
| Pathogenesis of antiphospholipid syndrome: understanding the antibodies | Q37873720 | ||
| Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review | Q37996153 | ||
| Obstetric and vascular APS: same autoantibodies but different diseases? | Q38013583 | ||
| Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis | Q38177962 | ||
| The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. | Q38362118 | ||
| The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus | Q38446538 | ||
| Clinical course of high-risk patients diagnosed with antiphospholipid syndrome | Q39934417 | ||
| Outcome of renal transplantation in systemic lupus erythematosus | Q41587448 | ||
| Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice | Q41927420 | ||
| Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus | Q41977234 | ||
| IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality | Q43672062 | ||
| Incidence of arteriovenous thrombosis and the role of anticardiolipin antibodies in hemodialysis patients | Q47796229 | ||
| Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus. | Q51030874 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis | Q71517613 | ||
| Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men | Q72369034 | ||
| Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: cause or effect? | Q73314967 | ||
| The antiphospholipid syndrome | Q77739053 | ||
| Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity | Q80213989 | ||
| The relationship between anticardiolipin antibodies and vascular access occlusion in patients on hemodialysis | Q81664877 | ||
| Antiphospholipid antibody syndrome | Q82234303 | ||
| Renal involvement in antiphospholipid syndrome | Q87467570 | ||
| P433 | issue | 5 | |
| P921 | main subject | kidney disease | Q1054718 |
| P304 | page(s) | 817-825 | |
| P577 | publication date | 2015-12-24 | |
| P1433 | published in | Rheumatology | Q7320492 |
| P1476 | title | Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study | |
| P478 | volume | 55 |
Search more.